Poukalov Konstantin
Insider CIK 1678736 · LYRA Director · KDMN Executive Vice President, CFO · LABP Director, 10% owner · LIAN Director · ARYD Chief Business Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| LYRA Lyra Therapeutics, Inc. | A Award deriv | 2024-06-13 | 2024-06-14 | 30,000 | — | $0 | 30,000 | SEC↗ |
| LIAN LianBio | M Exercise deriv | 2024-02-15 | 2024-02-20 | 36,300 | — | $0 | 0 | SEC↗ |
| LIAN LianBio | M Exercise | 2024-02-15 | 2024-02-20 | 36,300 | $2.52 | $91.5K | 36,300 | SEC↗ |
| LIAN LianBio | F Tax w/h | 2024-02-15 | 2024-02-20 | 19,218 | $4.76 | $91.5K | 17,082 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | A Award deriv | 2023-06-30 | 2023-07-05 | 20,000 | — | $0 | 20,000 | SEC↗ |
| LIAN LianBio | A Award deriv | 2023-06-21 | 2023-06-23 | 36,300 | — | $0 | 36,300 | SEC↗ |
| LIAN LianBio | A Award deriv | 2022-06-23 | 2022-06-27 | 36,300 | — | $0 | 36,300 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | A Award deriv | 2022-06-16 | 2022-06-21 | 7,250 | — | $0 | 7,250 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | A Award deriv | 2021-05-26 | 2021-05-28 | 7,250 | — | $0 | 7,250 | SEC↗ |
| LABP Landos Biopharma, Inc. | P Buy | 2021-02-09 | 2021-02-09 | 34,951 | $14.60 | $510.3K | 14,869,915 | SEC↗ |
| LABP Landos Biopharma, Inc. | P Buy | 2021-02-09 | 2021-02-09 | 64,730 | $13.80 | $893.3K | 14,834,964 | SEC↗ |
| LABP Landos Biopharma, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-08 | 7,486,190 | — | $0 | 0 | SEC↗ |
| LABP Landos Biopharma, Inc. | C Conversion deriv | 2021-02-08 | 2021-02-08 | 5,883,538 | — | $0 | 0 | SEC↗ |
| LABP Landos Biopharma, Inc. | C Conversion | 2021-02-08 | 2021-02-08 | 13,369,728 | — | $0 | 13,369,728 | SEC↗ |
| LABP Landos Biopharma, Inc. | P Buy | 2021-02-08 | 2021-02-08 | 1,250,000 | $16.00 | $20.00M | 14,619,728 | SEC↗ |
| LABP Landos Biopharma, Inc. | P Buy | 2021-02-08 | 2021-02-09 | 1,771 | $13.10 | $23.2K | 14,770,234 | SEC↗ |
| LABP Landos Biopharma, Inc. | P Buy | 2021-02-08 | 2021-02-09 | 86,671 | $12.53 | $1.09M | 14,768,463 | SEC↗ |
| LABP Landos Biopharma, Inc. | P Buy | 2021-02-08 | 2021-02-09 | 34,611 | $11.38 | $393.9K | 14,681,792 | SEC↗ |
| LABP Landos Biopharma, Inc. | P Buy | 2021-02-05 | 2021-02-09 | 27,453 | $11.14 | $305.8K | 14,647,181 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | A Award deriv | 2020-04-30 | 2020-05-01 | 14,500 | — | $0 | 14,500 | SEC↗ |
| KDMN Kadmon Holdings, Inc. | A Award deriv | 2017-12-08 | 2017-12-12 | 205,000 | — | $0 | 205,000 | SEC↗ |
| KDMN Kadmon Holdings, Inc. | A Award deriv | 2016-12-15 | 2016-12-16 | 350,000 | $4.66 | $1.63M | 350,000 | SEC↗ |
| KDMN Kadmon Holdings, Inc. | P Buy | 2016-11-11 | 2016-11-14 | 1,000 | $5.91 | $5.9K | 2,000 | SEC↗ |
| KDMN Kadmon Holdings, Inc. | P Buy | 2016-11-11 | 2016-11-14 | 1,000 | $5.96 | $6.0K | 1,000 | SEC↗ |
| KDMN Kadmon Holdings, Inc. | P Buy | 2016-11-11 | 2016-11-14 | 1,000 | $5.95 | $6.0K | 3,000 | SEC↗ |
| KDMN Kadmon Holdings, Inc. | P Buy | 2016-11-11 | 2016-11-14 | 1,000 | $5.43 | $5.4K | 4,000 | SEC↗ |